Real‐world effectiveness of abrocitinib treatment in patients with difficult‐to‐treat atopic dermatitis
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.19378 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von J I Olydam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Acne Vulgaris, Janus Kinase Inhibitors. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Abrocitinib is a JAK‐1 selective inhibitor registered for the treatment of moderate‐to‐severe atopic dermatitis (AD). Although efficacy and safety have been shown in phase 3 clinical trials, data on real‐world patients with a treatment history of advanced systemics are scarce.
Objectives
The objective of the study was to evaluate the effectiveness and safety of abrocitinib treatment in patients with difficult‐to‐treat AD in daily practice.
Methods
In this prospective observational single‐centre study, all AD patients who started abrocitinib treatment in the context of standard care between April 2021 and December 2022 were included. Effectiveness was assessed using clinician‐ and patient‐reported outcome measures. Adverse events were evaluated.
Results
Forty‐one patients were included. The majority ( n = 30; 73.2%) had failed (ineffectiveness) on other targeted therapies, including JAK inhibitors ( n = 14, 34%) and biologics ( n = 16, 39%). Abrocitinib treatment resulted in a significant decrease in disease severity during a median follow‐up period of 25 weeks (IQR 16–34). Median EASI score at baseline decreased from 14.7 (IQR 10.4–25.4) to 4.0 (IQR 1.6–11.4) at last review ( p < 0.001). Median NRS itch decreased from 7.0 (IQR 5–8) to 3.0 (IQR 1–2) at last review ( p < 0.001). The most frequently reported AEs included gastrointestinal symptoms (27.6%), acne (20.7%) and respiratory tract infections (17.2%). 16 (39%) patients discontinued abrocitinib treatment due to ineffectiveness, AEs or both (41.2%, 41.2% and 11.8%, respectively).
Conclusion
Abrocitinib can be an effective treatment for patients with moderate‐to‐severe AD in daily practice, including non‐responders to other targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
ORCID-Profile: J I Olydam, A R Schlösser, T E C Nijsten, D Hijnen
Zitieren
APA
Olydam, J. I., Schlösser, A. R., Custurone, P., Nijsten, T. E. C., & Hijnen, D. (2023). Real‐world effectiveness of abrocitinib treatment in patients with difficult‐to‐treat atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19378
Vancouver
Olydam JI, Schlösser AR, Custurone P, Nijsten TEC, Hijnen D. Real‐world effectiveness of abrocitinib treatment in patients with difficult‐to‐treat atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19378
BibTeX
@article{Olydam2023,
author = {Olydam, J I and Schlösser, A R and Custurone, P and Nijsten, T E C and Hijnen, D},
title = {Real‐world effectiveness of abrocitinib treatment in patients with difficult‐to‐treat atopic dermatitis},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.19378}
}
EUVIMED